These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32228295)

  • 1. Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.
    Alessandrino F; Williams K; Nassar AH; Gujrathi R; Silverman SG; Sonpavde G; Shinagare AB
    Radiology; 2020 Jun; 295(3):572-580. PubMed ID: 32228295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
    Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
    Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
    Aggarwal R; Romero GR; Friedl V; Weinstein A; Foye A; Huang J; Feng F; Stuart JM; Small EJ
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):81-87. PubMed ID: 32286548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial carcinoma: association between mutational status, sites of metastasis, recurrence, and correlation with overall survival.
    Luna C; Goncalves N; Metalonis SW; Mason MM; Lyu J; Huang M; Alessandrino F
    Abdom Radiol (NY); 2023 Aug; 48(8):2684-2694. PubMed ID: 37289213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma.
    Kobayashi M; Tanaka H; Tateishi U; Numao N; Yonese J; Ito M; Koga F; Fukushima H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    Int J Urol; 2019 Aug; 26(8):820-826. PubMed ID: 31140215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic Heterogeneity of Breast Cancer Determined Using Computer-aided Diagnosis of Preoperative MRI Scans: Relationship to Distant Metastasis-Free Survival.
    Kim JY; Kim JJ; Hwangbo L; Suh HB; Kim S; Choo KS; Nam KJ; Kang T
    Radiology; 2020 Jun; 295(3):517-526. PubMed ID: 32228293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
    Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F
    Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.
    Bingham C; Fernandez SV; Fittipaldi P; Dempsey PW; Ruth KJ; Cristofanilli M; Katherine Alpaugh R
    Breast Cancer Res Treat; 2017 Jun; 163(2):219-230. PubMed ID: 28271309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.